KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2026;40(1):61-66 / www.klinickafarmakologie.cz 66 PŘEHLEDOVÉ ČLÁNKY Cílená léčba psoriatické artritidy LITERATURA 1. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. 2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957-970. 3. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-719. doi: 10.1136/ard-2024-225531. PMID: 38499325; PMCID: PMC11103320. 4. Vincken NLA, Balak DMW, Knulst AC, et al. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Rheumatology. 2022;61:4232-4244. 5. Felten R, Lambert De Cursay G, et al. Is there still a place for methotrexate in severe psoriatic arthritis. Ther Adv Musculoskelet Dis 2022;14. doi: 10.1177/1759720X221092376. 6. Eder L, Mathew AJ, Carron P, et al. Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(2):258-264. 7. Lubrano E, Chan J, Queiro-Silva R, et al. Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(2):279-284. 8. Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017;10(8):899-910. 9. Lindström U, Di Giuseppe D, Delcoigne B, et al. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Ann Rheum Dis 2021;80:1410-1418. 10. Regierer AC, Kiefer D, Schett G, et al. No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry. RMD Open. 2024;10(3):e004389. 11. Coates LC, Mease P, Kronbergs A, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clin Rheumatol. 2022;41(10):3035-3047. 12. Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483-494. 13. Nie T, Shirley M. Bimekizumab: A Review in Psoriatic Arthritis. Drugs. 2024;84(5):587-598. 14. Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023;62(4):1417-1425. 15. Nakamura A, Chandran V. Risankizumab for the treatment of active psoriatic arthritis in adults. Expert Rev Clin Immunol. 2023;19(12):1435-1448. 16. Kavanaugh A, Ritchlin C, Rahman P, et al. PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000-1006. 17. Paik J, Deeks ED. Tofacitinib: A Review in Psoriatic Arthritis. Drugs. 2019;79(6):655-663. 18. Marchesoni A, Citriniti G, Girolimetto N, et al. Upadacitinib for the treatment of adult patients with active psoriatic arthritis. Expert Rev Clin Immunol. 2024;20(5):423-434. 19. Schett G. Apremilast in psoriatic arthritis. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S98-100. 20. Pavelka K, Mann H, Výbor České revmatologické společnosti. Doporučení České revmatologické společnosti pro léčbu psoriatické artritidy. Čes Revmatol. 2023;31(2):63-74. 21. Queiro R, Loredo M, Brana I, et al. Managing psoriatic arthritis in different clinical scenarios. Expert Rev Clin Immunol. 2023;19(12):1469-1484. 22. Lumetti F, Ariani A, Marchesoni A, et al. Cycling versus swapping strategies with TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice. Sci Rep. 2024;14(1):24922. 23. Esti L, Fattorini F, Cigolini C, et al. Clinical aspects of psoriatic arthritis: one year in review 2024. Clin Exp Rheumatol. 2025;43(1):4-13.
RkJQdWJsaXNoZXIy NDA4Mjc=